The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The importance of treating high-risk smoldering myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, emphasizes the importance of treating patients with high-risk smoldering multiple myeloma (SMM). Indeed, Dr Cerchione explains that the combination of lenalidomide and dexamethasone has been shown to help prevent progression to symptomatic multiple myeloma. He further notes that the addition of a monoclonal antibody to this treatment could be of benefit to this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
